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by HPLC. SW1353 and primary human chondrocytes obtained after total
knee replacement surgery from patients with osteoarthritis (OA) were
cultured in DMEM with 10% FCS. Cytotoxicity of different CSE concentra-
tions was examined using MTT and BrdU assays. Quantitative real-time
RT-PCR (RT-qPCR) was used to evaluate the effects of CSE on mRNA
levels of interleukin-1-beta (IL-1β), tumor necrosis factor-alpha (TNF-α), in-
ducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and matrix
metalloproteinase-3 (MMP-3). The nitric oxide (NO) production was mea-
sured using Griess assay. The gelatinolytic activity of MMPs was determined
by zymography. Transient transfection and luciferase assay was performed
to study CSE action on NF-kappaB signalling.
Results: Dose-response experiments revealed that up to 20 μg/ml CSE did
not impair viability of chondrocytes. CSE treatments (5-20 μg/ml) signif-
icantly suppressed the up-regulation of proinﬂammatory cytokine mRNA
(IL-1β and TNF-α) in response to IL-1β (10 ng/ml) stimulation in SW1353
and primary chondrocytes (p<0.05). At the same concentrations, CSE in-
hibited the IL-1β induced up-regulation of MMP3 mRNA and gelatinolytic
activity of MMPs in a dose-dependent manner. A signiﬁcant inhibition of
NO production and iNOS mRNA expression was also observed in IL-1β
stimulated primary chondrocytes pretreated with CSE (p<0.05). Cotrans-
fections of the COX-2 promoter luciferase reporter plasmid together with
p50 and p65 expression vectors enhanced the COX-2 promoter activity
3.4-fold in SW1353 cells. This p50/p65-mediated transactivation of the
COX-2 promoter was dose-dependently down-regulated to basal levels by
CSE.
Conclusions: These results indicate that CSE possesses potent anti-
inﬂammatory activity in osteoarthritic chondrocytes. In particular, its
action might involve the inhibition of NO production via iNOS downreg-
ulation as well as the inhibition of p50/p65-mediated COX-2 promoter
activation.
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Purpose: Osteoarthritis (OA) progression is accompanied by a reduction
of extracellular matrix and increased catabolism of collagen ﬁbers and
glycosaminoglycans in joints. Cyclooxygenase-inhibiting nitric oxide dona-
tors (CINODs) are novel anti-inﬂammatory compounds designed to provide
balanced COX-1 and COX-2 inhibition while releasing nitric oxide (NO),
an important modulator of vascular tone. In the cartilage, the role of
NO is controversial, as it is a recognized marker of inﬂammation and a
possible cause of chondrocyte loss, but also a potent immuno-modulating
factor improving joint vascular perfusion. We investigated the effects of the
CINOD NCX 429 and reference NSAIDs (naproxen and celecoxib) in stim-
ulated adult rabbit chondrocytes, focusing on their catabolic and anabolic
activities, as well as inﬂammatory parameters.
Methods: Primary cultures of adult rabbit (4-6 months) articular chondro-
cytes (RACs) were pre-incubated with test drugs (1-10 μM, 8 hours) before
addition of IL-1β (10 ng/ml, 16 additional hours) in 5% O2 conditions, to
mimic joint limited perfusion. Levels of mRNA were determined by quan-
titative RT-PCR for assessing expression of extracellular matrix proteins
(aggrecan and collagen type II) and matrix proteases [aggrecanases and
matrix metalloproteases (MMPs)]. NO production was determined by mea-
surement of nitrite/nitrate (NOx) using the Griess method. Type II collagen
production was evaluated in the supernatant by Western blot analysis. To
assess COX inhibition, prostaglandin E2 (PGE2) was measured by enzyme
immunoassay in the supernatant of IL-1β stimulated chondrocytes (from 2
months-old rabbits) incubated with NCX 429 (1-100 μM).
Results: NCX 429 and naproxen did not show any impact on RAC viability.
In IL-1β-stimulated RACs, NCX 429 induced a 2-fold increase in type II col-
lagen expression, similarly to naproxen and celecoxib. NCX 429 stimulated
type II collagen at both mRNA and protein levels. In addition, NCX 429 re-
duced IL-1β-stimulated expression of MMP-1 by ∼ 50% and aggrecanase-1
and 2 expression (by ∼ 50% and 40%, respectively), with similar eﬃcacy
to naproxen and celecoxib. Conversely, IL-1β-induced increase in MMP-3
and decrease in aggrecan expression were not prevented by NCX 429 or
naproxen, whereas celecoxib inhibited MMP-3 expression by 40%. Inter-
estingly, while naproxen and celecoxib increased IL-1β-stimulated NOx
levels by ∼ 50 and 30%, respectively, NCX 429 decreased NOx levels (by
∼ 25%). Finally, NCX 429 inhibited IL-1β-induced PGE2 biosynthesis in a
concentration-dependent manner, indicating effective COX inhibition.
Conclusions: NCX 429, naproxen and celecoxib modulate IL-1β-induced
expression of catabolic and anabolic markers in stimulated adult rabbit
articular chondrocytes. Interestingly, the CINOD NCX 429 slightly reduces
IL-1β-induced increase of endogenous NO synthesis, differently from the
other NSAIDs, likely by inhibiting inducible nitric oxide synthase (iNOS)
expression, as already reported for other CINODs. NO has been considered
as potentially detrimental for chondrocytes; however, donation of low
concentrations of NO from the CINOD NCX 429 does not seem to affect
chondrocyte survival or to increase the expression of mediators involved
in cartilage degeneration. CINODs may even inhibit endogenous overpro-
duction of NO, and therefore may represent an interesting therapeutic
approach for the treatment of osteoarthritis.
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Purpose: To establish if the ribonucleinate components of the osteo-
arthritis natural drug, Osteochondrin® S (OST) affect the bone-resorbing
functions and gene expression in osteoclasts.
Methods: Human osteoclasts were generated in vitro from culture of
RANKL-M-CSF stimulated peripheral blood mononuclear cells for 17d. Cells
were treated with 23.5-587.2 ng/mL OST or 0.2-5 mg/mL RNA components
of connective tissues or yeast (as used to make OST) and their effects on
osteoclast formation were assessed using a Tartrate-Resistant Acid Phos-
phatase (TRAP) stain. Cell were also grown on dentine slices and used to
determine the effects on osteoclast bone resorption was The pit formation
on dentine was determined by scanning electron microscopy. In separate
experiments, real time PCR was used to determine mRNA expression of
principal enzymes or signalling molecules governing osteoclast functions.
Results: OST and its RNA components showed approximately equiva-
lent concentration-dependent inhibition of TRAP stained osteoclasts and
associated reduction in pit formation on dentine (Fig. 1A–F).
OST was, however, more potent in preventing bone resorption than the
individual RNAs. mRNA expression of calcitonin receptor (CTR) was reduced
Figure 1A–F: Effects of OST and RNA components on osteoclast-mediated bone resorp-
tion. Statistical signiﬁcance (***p<0.001; *p<0.05) - one-way ANOVA.
